An engineered S. cerevisiae aimed at the in vivo treatment of melanoma was developed. The cell was equipped with immune modulators IFN γ and GM-CSF and injected into the tumor. Further, CD4+ and CD8+ T cells were elicited with a yeast antigen display system. Here, CD8A is linked to melanoma.